在接受过导管大动脉植入术的患者中进行抗血栓治疗
Francesco Pallante1, Francesco Costa2,3, Victoria Garcia Ruiz3
1Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
Journal of clinical medicine
|July 13, 2024
概括
过导管大动脉植入 (TAVI) 是严重的大动脉狭窄症的关键治疗方法. 最佳的抗血栓治疗对长期结果至关重要,平衡标准指南与个性化患者需求.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
背景情况:
- 透导管大动脉植入 (TAVI) 是重症大动脉狭窄的主要治疗方法,现在包括低风险患者.
- 塔维的长期成功在很大程度上依赖于有效的二次血管预防,而抗血栓治疗是核心的.
研究的目的:
- 审查支持TAVI后抗血栓治疗的证据.
- 讨论基于患者因素的标准化治疗指示和个性化方法.
主要方法:
- 分析来自多个随机对照试验的数据.
- 对TAVI后抗血栓治疗的当前指导方针的审查.
主要成果:
- 目前的指南建议单次抗血小板治疗 (SAPT) 或口服抗凝剂 (OAC) 单独使用.
- 针对特定的患者形状和并发手术,可能需要个性化抗血栓治疗策略.
结论:
- 抗血栓治疗对于TAVI患者的最佳长期结果至关重要.
- 对抗血栓治疗通常需要量身定制的方法,超出标准指导方针.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672


